. 2019 Jan 28;20(3):553. doi: 10.3390/ijms20030553

Table A1.

The expression levels of predicted microRNA targets in asthma/chronic obstructive pulmonary disease (COPD) bronchial epithelial cells.

Number of Databases Suggesting the microRNA-mRNA Relationship		Source	GSE67940		GSE41861		GSE41861		GSE63142		GSE43696		GSE4302		GSE38974		GSE20257
		n (Control)	31 control		30 control		30 control		27 control		20 control		28 control		9 control		53 control
		n (Case)	73 asthma		26 asthma (moderate & severe)		51 asthma		128 asthma		88 asthma (moderate & severe)		42 asthma		23 COPD		23 COPD
miR-10a-5p	miR-146a-5p	Gene	adj. p	log₂FC	adj. p	log₂FC	adj. p	log₂FC	adj. p	log₂FC	adj. p	log₂FC	adj. p	log₂FC	adj. p	log₂FC	adj. p	log₂FC
8	3	FOXO3	0.04	−0.24					0.85	−0.02	0.84	−0.04	0.84	0.07	0.06	−0.47	0.46	0.22
8	8	GRIN3A	0.98	−0.01					0.34	0.18	0.41	0.27	0.39	−0.10	0.93	−0.04	0.03	0.70
7	3	ADRB3	0.66	0.10	0.93	0.01	0.90	0.01	0.39	0.13	0.12	0.42	0.87	−0.02	0.36	−0.23	0.25	0.40
7	4	BCL2	0.92	−0.05	0.01	−0.41	0.01	0.13	0.29	−0.11	0.51	−0.16	0.60	−0.04	0.06	−0.51	0.49	−0.27
2	7	CD8A	0.96	−0.06	0.88	0.05	0.84	0.06	0.85	−0.07	0.83	−0.13	0.98	−0.01	0.67	−0.18	0.04	0.78
7	7	GRIN2A	0.63	−0.20	0.74	0.03	0.51	0.04	0.56	−0.03	0.69	0.14	0.78	−0.03	0.32	−0.32	0.31	0.49
3	7	HDAC2	0.41	0.08	0.01	0.17	0.02	0.13	0.67	0.04	0.97	0.01	0.88	0.03	0.43	−0.27	0.06	0.54
	7	MPO	0.62	0.22	0.58	0.04	0.30	0.05	0.97	0.00	0.91	0.05	0.57	0.03	0.16	0.55	0.63	−0.25
	6	CCL5	0.89	−0.15	0.63	0.15	0.47	0.19	0.95	−0.04	0.96	−0.05	0.45	0.13	0.80	−0.11	0.27	0.50
5	6	CYSLTR2	0.51	0.16	0.84	−0.02	0.83	−0.01	0.94	0.01	0.83	0.10	1.00	0.00	0.62	−0.14	0.87	0.08
6		GATA3	0.94	−0.03	0.58	−0.08	0.88	0.03	0.74	0.06	0.91	−0.09	0.49	−0.07	0.71	−0.12	1.00	0.00
6		HMGCR	0.86	−0.05	0.28	−0.13	0.03	−0.21	0.93	−0.02	0.48	0.20	0.11	−0.22	0.78	−0.08	0.69	0.14
3	6	PDE11A	0.19	−0.48					0.53	0.04	0.57	0.16	0.10	−0.17	0.23	−0.30	0.07	0.69
6	6	PDE3A	0.86	0.02	0.98	0.00	0.87	0.01	0.96	−0.01	0.95	−0.03	0.69	−0.03	0.43	−0.19	0.76	−0.18
6		PDE4A	0.01	−0.23	0.57	−0.05	0.40	−0.06	0.73	0.03	0.08	−0.24	0.45	0.07	0.05	−0.28	0.46	0.23
	6	PDE7B	0.87	0.09	0.28	−0.09	0.00	−0.35	0.82	−0.02	0.28	−0.24	0.25	0.06	0.71	−0.14	0.20	−0.44
2	6	PGR	0.52	0.13					0.66	−0.03	0.59	−0.16	0.57	−0.04	0.05	−0.40	0.80	−0.14
6	3	VDR	0.81	−0.05	0.42	0.05	0.08	0.08	0.77	0.05	0.95	−0.02	0.55	0.04	0.05	0.50	0.29	0.42
5	2	CRP	0.10	−0.45					0.96	0.01	0.93	0.06	0.89	0.02	0.60	0.19	0.61	−0.24
5	5	CTSS	0.37	0.15	0.10	0.20	0.10	0.17	0.68	−0.09	0.76	−0.11	0.56	−0.06	0.00	2.14	0.36	0.24
5		FGFR3	0.89	0.05	0.00	−0.49	0.01	−0.37	0.48	−0.16	0.85	−0.10	0.80	0.02	0.06	−0.48	0.40	−0.26
3	5	GRIN2B	0.72	0.09	0.73	0.03	0.52	0.05	0.98	0.00	0.63	0.07	0.44	−0.06	0.74	0.11	0.03	1.04
5	5	PDE7A	0.70	−0.15	0.02	−0.23	0.00	−0.38	0.03	−0.23	0.57	−0.12	0.17	−0.08	0.23	−0.38	0.09	0.66
	5	SELE	0.66	−0.22					0.88	0.01	0.98	0.01	0.68	−0.03	0.15	1.34	0.40	0.44
	5	TARP	0.94	0.04					0.87	−0.04	0.79	−0.17	0.72	0.05	0.84	−0.08	0.14	−0.60
5		TBX21	0.98	−0.02	0.40	0.08	0.37	0.07	0.90	0.02	0.97	0.03	0.45	0.08	0.50	−0.31	1.00	0.00
	4	CHRM1	0.98	0.01					0.27	0.10	0.30	0.29	0.55	0.04	0.35	−0.21	0.13	0.66
3	4	CHRM2	0.72	0.12					0.82	−0.02	0.73	−0.12	0.79	−0.02	0.00	−1.22	0.90	0.07
	4	CHRM3	0.67	0.15	0.29	−0.09	0.28	−0.06	0.41	−0.04	0.46	−0.37	0.17	0.09	0.00	−1.32	0.35	−0.46
4		GRIN1	0.72	0.16	0.27	0.07	0.26	0.10	0.04	0.35	0.07	0.40	0.53	0.05	0.73	0.08	0.44	0.32
4		GRIN2C	0.83	0.07	0.41	0.05	0.85	0.02	0.51	0.08	0.63	0.21	0.94	−0.01	0.92	−0.04	0.32	0.44
4		HLA−DQA1	0.75	−0.37	0.89	0.13	0.98	0.03	0.24	−0.22	0.62	0.40	0.52	−0.55	0.66	0.75	0.50	−0.66
2	4	INSR	0.87	−0.04	0.00	−0.48	0.00	−0.33	0.01	−0.27	0.04	−0.38	0.22	−0.32	0.17	−0.56	0.26	−0.34
	4	MYLK	0.75	0.24	0.45	0.09	0.93	−0.02	0.43	−0.10	0.68	−0.12	0.49	0.13	0.01	−0.75	0.10	0.59
	4	PDE4B	0.26	−0.47	0.54	0.06	0.44	0.06	0.57	−0.14	0.58	−0.11	0.22	−0.11	0.35	−0.22	0.04	0.91
4		PDE4C	0.20	−0.34					0.41	−0.11	0.78	−0.07			0.01	−0.54
2	4	PDE4D	0.67	−0.32	0.76	−0.02	0.57	0.05	0.59	0.05	0.17	−0.31	0.42	0.08	0.12	−0.34	0.26	0.33
3	2	ADRA1A	0.55	−0.24					0.94	0.01	0.65	0.21	0.67	0.03	0.42	0.28	0.37	0.48
3	2	ADRB2	0.00	0.58	0.56	−0.09	0.26	−0.12	0.49	0.13	0.45	0.23	0.72	−0.10	0.04	−0.79	0.53	0.17
3		CHRNA4	0.55	0.10	0.49	0.06	0.10	0.11	0.55	0.13	0.46	0.24	0.60	0.05	0.77	−0.07	0.64	0.14
3	2	CHRNB2	0.81	−0.11	0.52	0.06	0.31	0.07	0.96	0.02	0.61	0.20	0.45	0.07	0.12	0.32	0.46	0.28
3	2	HMOX1	0.79	0.04	0.38	−0.22	0.12	−0.30	0.67	−0.15	0.59	−0.26	0.42	−0.13	0.01	1.32	0.34	0.34
2	3	HRH1	0.08	−0.30	0.16	0.11	0.06	0.12	0.38	0.08	0.28	0.34	0.48	0.08	0.00	0.84	0.25	0.45
3		IL13	0.69	0.24	0.49	0.06	0.11	0.11	0.37	0.07	0.76	0.17	0.17	0.10	0.55	0.49	0.07	0.71
2	3	IL6	0.87	−0.10	0.24	−0.21	0.04	−0.25	0.01	−0.36	0.05	−0.94	0.87	0.02	0.01	2.37	0.61	−0.26
2		ADORA2A	0.76	−0.11					0.81	0.02	0.66	0.12			0.00	0.57
	2	CHRNA7	0.92	−0.03					0.50	−0.07	0.84	−0.08			0.32	−0.27
2		IL10	0.57	0.21					0.96	−0.01	0.79	−0.12	0.84	0.01	0.05	0.65	0.21	0.54
	2	IL1R1	0.77	0.10	0.17	−0.20	0.73	−0.06	0.73	−0.05	0.76	−0.10	0.56	0.06	0.40	0.22	0.80	0.12
2	2	IL2RA	0.93	0.07	NA	NA	NA	NA	0.45	0.08	0.67	0.20	0.75	−0.03	0.01	1.04	0.55	0.23
2		NOS2	0.48	0.58					0.01	1.10	0.08	1.15	0.02	0.29	0.50	0.31	0.65	0.24
	2	PDE3B	0.71	−0.10	0.70	0.03	0.56	0.04	0.52	0.07	0.87	0.08	0.76	0.02	0.13	0.29	0.02	0.99
	2	PDE5A	0.78	−0.09	0.25	0.08	0.17	0.08	0.93	0.01	0.50	−0.25	0.46	−0.05	0.00	−0.79	0.38	0.43
	2	TNF	0.55	0.15	0.92	−0.02	0.46	−0.08	0.76	0.03	0.87	0.10	0.90	0.02	0.27	−0.24	0.27	0.43

The data from the Gene Expression Omnibus (GEO) database were analyzed with GEO2R. The p values adjusted with method by Benjamini and Hochberg (false discovery rate) (adj. p) and log₂-fold change (Log₂FC) between two groups (asthma/COPD vs. control) were shown. The results of significant (adj. p value <0.25) down-regulation in the asthma/COPD group were highlighted with yellow background; the gene names with at least one significant down-regulation in both asthma and COPD databases were also highlighted with orange background.